Repligen Concludes Pre-NDA Meeting with FDA for RG1068
Repligen Corporation today announced that the Company has concluded a pre-New Drug Application meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

FDA biopharmaceutical drug approvals increase despite slower development time
The U.S. Food and Drug Administration has passed nearly twice as many biopharmaceutical drug approvals in the last 10 years than it did in the 1990s, a news release from the Tufts Center for the Study of Drug Development has indicated.